Radiation therapy is not a standard treatment for osteoarthritis (OA) in the United States, but it has been explored and utilized in some European countries.
Low-dose radiation therapy (LDRT) for arthritis — most commonly studied for painful osteoarthritis (OA) — remains an investigational, controversial option whose benefit over placebo is unproven.
The primary role of low-dose radiation therapy (LDRT) in osteoarthritis (OA) is to provide pain relief and improve joint function through its anti-inflammatory effects.
Low-dose radiation therapy (LDRT) for arthritis — mostLow-dose radiation therapy (LDRT) for arthritis — most commonly studied for painful osteoarthritis (OA) — remains an investigational, controversial option whose benefit over placebo is unproven.
Several studies have demonstrated the potential benefits of LDRT in managing OA symptoms.
LDRT can offer moderate to long-term pain relief and improved mobility in OA-affected joints, with minimal side effects.
LDRT can reduce pain and enhance function in OA patients, with mechanistic insights suggesting modulation of inflammatory pathways.
The highest-quality evidence does not clearly demonstrate benefit beyond a placebo effect.
Preclinical evidence that LDRT can mitigate OA progression by reducing pro-inflammatory factors and enhancing mitochondrial function in chondrocytes and synoviocytes.
LDRT can lead to significant pain reduction and improved joint mobility, particularly in younger patients.
The typical dosage for LDRT in OA treatment ranges from 0.3 Gy to 3 Gy, administered in fractions over several sessions.
Radiation therapy is sometimes used as a treatment for osteoarthritis, though it’s not considered a first-line treatment in most cases. Let me share some information about radiation therapy for osteoarthritis:
Low-dose radiation may help reduce inflammation and pain by affecting inflammatory cells and reducing cytokine production.
Two types of treatment:
1. Radiosynovectomy (radiosynoviorthesis)— a radioactive isotope is injected directly into an inflamed joint to shrink the swollen synovial lining.
Used mainly for rheumatoid arthritis and other inflammatory joint diseases when other treatments haven’t controlled the swelling.
2. Low-dose radiotherapy (LD-RT)— external beam radiation at very low doses (much lower than cancer treatment), used for painful osteoarthritis, especially in joints like the knee, hip, shoulder, and heel (plantar fasciitis is also sometimes treated this way).
Numerous single-arm retrospective and prospective cohorts report meaningful pain relief, improved mobility, and minimal side effects.
A recent U.S. single-institution series of 69 patients/168 joints (3 Gy in 6 fractions of 0.5 Gy over 2–3 weeks) found significant pain reduction sustained at 10-week follow-up, with ~80% of joints improving at end of treatment and 72% maintaining improvement.
However, several randomized double-blind sham-controlled trials have found no additional benefit of LDRT over sham.
Proponents argue these RCTs were limited by small samples, short follow-up, suboptimal patient selection, and protocol deviations, while critics note the placebo response in OA is so potent that unblinded observational data are unreliable.
A 2026 Expert Perspective in Arthritis & Rheumatology concluded that the evidence base is sparse and that accumulating data suggest LDRT may not provide incremental benefit above placebo, advising rheumatologists to be circumspect about recommending it outside of well-designed RCTs.
Standard regimens deliver 3.0–6.0 Gy total in 0.5–1.0 Gy fractions over 2–3 weeks, with a second course sometimes offered to nonresponders.
Safety. LDRT is noninvasive and generally well tolerated with minimal acute side effects.
The absolute risk of radiation-induced malignancy is considered negligible in elderly populations, but this concern is why it is typically reserved for older patients; shielding and cumulative dose monitoring are advised, and it is not favored in younger patients.
Numerous single-arm retrospective and prospective cohorts report meaningful pain relief, improved mobility, and minimal side effects.
A recent U.S. single-institution series of 69 patients/168 joints (3 Gy in 6 fractions of 0.5 Gy over 2–3 weeks) found significant pain reduction sustained at 10-week follow-up, with ~80% of joints improving at end of treatment and 72% maintaining improvement.
However, several randomized double-blind sham-controlled trials have found no additional benefit of LDRT over sham.
Proponents argue these RCTs were limited by small samples, short follow-up, suboptimal patient selection, and protocol deviations, while critics note the placebo response in OA is so potent that unblinded observational data are unreliable.
A 2026 Expert Perspective in Arthritis & Rheumatology concluded that the evidence base is sparse and that accumulating data suggest LDRT may not provide incremental benefit above placebo, advising rheumatologists to be circumspect about recommending it outside of well-designed RCTs.
Standard regimens deliver 3.0–6.0 Gy total in 0.5–1.0 Gy fractions over 2–3 weeks, with a second course sometimes offered to nonresponders.
Safety. LDRT is noninvasive and generally well tolerated with minimal acute side effects.
The absolute risk of radiation-induced malignancy is considered negligible in elderly populations, but this concern is why it is typically reserved for older patients; shielding and cumulative dose monitoring are advised, and it is not favored in younger patients.
The putative anti-inflammatory/analgesic effect is attributed to modulation of innate immunity — reduced leukocyte–endothelial adhesion, macrophage polarization toward an M2 anti-inflammatory phenotype, apoptosis of activated fibroblast-like synoviocytes, reduced osteoclast activity, and a shift toward anti-inflammatory cytokines.
LDRT may be considered for elderly patients with refractory, symptomatic OA who have exhausted conservative measures (physiotherapy, NSAIDs, intra-articular injections) and are unfit for surgery, but it should be framed as unproven pending adequately powered, blinded RCTs.
It doesn’t reverse joint damage — it targets pain and inflammation, not the underlying structural disease.